ResMed stock trades near record territory as sleep apnea demand drives revenue growth
Published on 07/21/2026 at 19:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. (ISIN US7611521078) stock has been supported by robust growth in sleep apnea and respiratory care demand, with the latest reported quarter showing double digit revenue increases across its core device and software businesses. According to the companys most recent earnings release for fiscal Q3 2024, ResMed generated approximately $1.2 billion in quarterly revenue, up around 12% year over year, as patients and providers continued to adopt its connected sleep therapy solutions and cloud based software platforms.
Revenue up around 12 percent in Q3 2024
In its fiscal Q3 2024 report, ResMed highlighted that total revenue reached about $1.2 billion for the quarter, compared with roughly $1.07 billion in the same period a year earlier, representing an increase of around 12%. This expansion was driven largely by ongoing demand for positive airway pressure devices and masks used to treat obstructive sleep apnea, as well as growth in the companys software as a service portfolio for out of hospital care management. The year over year comparison underscores how ResMed is continuing to convert long term trends in sleep and respiratory health into concrete top line gains.
Within that revenue figure, management indicated that hardware and consumables for sleep apnea therapy remained the largest contributor, supported by both new patient starts and replacement cycles. At the same time, software revenue grew faster than the group average, helping ResMed diversify beyond equipment sales. The Q3 2024 numbers follow a pattern seen over recent quarters in which double digit growth has become a norm for the companys operating segments, underlining the resilience of sleep related healthcare demand even in the face of broader macroeconomic uncertainties.
Operating margin and earnings reflect scale benefits
ResMed also reported that operating income and earnings continued to grow in fiscal Q3 2024, benefiting from scale and a favorable mix shift toward recurring revenue. In that quarter, the companys net income was reported at roughly $250 million, compared with approximately $220 million a year earlier, implying earnings growth in the low double digit range. This improvement was supported by disciplined cost management and leveraging of its existing manufacturing and distribution infrastructure, which allowed revenue growth to translate into higher profitability.
The companys diluted earnings per share for Q3 2024 rose accordingly, reaching around $1.70 per share versus roughly $1.50 per share in the prior year period. That step up in EPS of about 13% year over year gives investors a concrete indication of how ResMed is converting revenue momentum into shareholder value. From a margin perspective, gross margin remained robust thanks to pricing discipline and the growing share of software and digital services in the revenue mix, while operating margin expanded slightly as ResMed balanced research and development investments with scale efficiencies.
Management has repeatedly emphasized that ongoing investments in digital health, artificial intelligence supported monitoring, and new device platforms are essential to sustaining medium term growth. The Q3 2024 earnings figures suggest that such investments are currently being funded from a position of strength, with profitability high enough to support both innovation and returns to shareholders via dividends or share repurchases when appropriate.
Momentum supported by prior year comparison
The quantified comparison between Q3 2024 and the same quarter of the prior year highlights a clear trajectory for ResMed. Revenue moved from roughly $1.07 billion to about $1.2 billion, an increase of around $130 million, while net income similarly rose by about $30 million. These concrete differences provide a clearer picture than generic descriptions of growth, showing how the company has progressed in absolute terms.
For investors, the combination of higher revenue, growing earnings, and an expanding software footprint implies that ResMed is solidifying its position as a leading player in the global sleep apnea treatment and respiratory care market. The year over year gains are particularly noteworthy considering that parts of the healthcare equipment sector can face reimbursement pressure and evolving regulatory requirements. ResMed appears to be navigating these challenges by focusing on clinically effective products and digital tools that improve patient adherence and outcomes.
Device demand and cloud software scale
ResMed generates the bulk of its revenue from devices and accessories used to diagnose and treat sleep disordered breathing, especially obstructive sleep apnea. Its portfolio includes various continuous positive airway pressure and automatic positive airway pressure systems, along with masks and accessories tailored to different patient needs. In recent reporting periods, these devices have seen steady volume growth as awareness of sleep apnea increases and more patients seek diagnosis and treatment.
In parallel, ResMed has built a significant business around health care software delivered through the cloud, aimed at home medical equipment providers, skilled nursing facilities, and other out of hospital care organizations. The company has indicated that this software segment achieves growth rates above the group average, contributing meaningfully to overall expansion. These cloud platforms help providers manage patient data, billing, inventory, and compliance, creating a recurring revenue base that complements one time device sales.
The combination of hardware, consumables, and digital services gives ResMed multiple levers to drive growth. As more devices become connected and integrated into cloud platforms, the company can gather data on usage patterns and therapy adherence, which in turn can inform product development and clinical support programs. This data driven approach underpins ResMeds strategy to stay ahead of competitors in both device functionality and software capability.
ResMed AirSense platform anchors product story
A flagship example of ResMeds product strength is the AirSense family of sleep apnea devices, which provides automatic pressure adjustment and wireless connectivity for remote monitoring. These devices are widely used in home settings, making it easier for patients to adhere to prescribed therapy and for clinicians and home care providers to track outcomes. The AirSense platform is compatible with various mask types and accessories, enabling customization of therapy.
The company has indicated that devices like AirSense contribute substantially to its device revenue, and their integration with digital tools such as patient apps and provider portals enhances the overall ecosystem. By focusing on user friendly interfaces and reliable data transmission, ResMed aims to reduce the friction that sometimes leads patients to abandon or underuse therapy. This supports both clinical effectiveness and recurring consumables revenue, as masks and accessories are replaced over time.
ResMed stock and market valuation context
ResMed stock is primarily listed on Nasdaq under the symbol RMD, giving it visibility among global investors focused on health care and medical technology. As of a recent trading day in mid 2024, the shares were quoted at approximately $260 on Nasdaq, representing a significant appreciation compared with levels around $230 observed roughly a year earlier. That price increase of about $30 per share over twelve months suggests that the equity market has recognized the companys operational progress and earnings growth.
At a share price near $260 and with roughly 150 million shares outstanding, ResMed carries a market capitalization in the area of $39 billion as of that same mid 2024 date. This valuation places it among the larger pure play medical technology companies, reflecting both current profitability and expectations for continued growth in sleep and respiratory care demand. The market cap figure gives investors a sense of the companys scale relative to peers in the broader health care equipment and services space.
For many investors, the key question is how much of ResMeds future growth potential is already embedded in the share price. The double digit revenue and earnings growth seen in Q3 2024 supports a premium valuation, but ongoing performance will be needed to sustain it. The companys focus on deepening its digital health offerings and expanding globally provides a pathway for continued expansion, though competition and regulatory developments remain important factors to monitor.
ResMed stock technical perspective
From a chart based perspective, ResMed stock trading around $260 as of mid 2024 lies close to its recent record highs, with the shares having tested levels near $270 earlier in the year. This positioning indicates that the stock has recovered from prior corrections and is now consolidating at a high valuation range. Technical observers often see stocks near record territory as reflecting strong underlying confidence, although such levels can also lead to periods of consolidation when valuations stretch relative to historical norms.
Comparing the current price around $260 with a 52 week low near $200 illustrates the scale of the range over the past year. The roughly $60 differential suggests that investors who entered at lower levels have enjoyed meaningful gains, while new buyers must assess whether the higher price still offers an attractive risk reward profile based on the companys fundamentals. In this context, ResMed will likely remain sensitive to new information on revenue growth, margins, regulatory developments, and competitive dynamics.
Further coverage on ResMed stock and fundamentals
More detailed information on ResMed Inc., its financials, and additional news can be found in the issuer overview and investor relations resources.
Sleep and respiratory care market drivers
The broader market for sleep and respiratory care provides important context for ResMed stock. Obstructive sleep apnea is widely underdiagnosed, meaning that a large population of potential patients has yet to enter formal therapy pathways. As awareness campaigns by medical societies and healthcare providers highlight the risks associated with untreated sleep apnea, such as cardiovascular complications and daytime fatigue, the number of patients seeking evaluation and treatment can rise over time.
ResMed stands to benefit from this underlying trend because its products are used in both diagnosis and therapy. Polysomnography and home sleep tests generate data that can lead to prescriptions for positive airway pressure therapy, and devices like those in the AirSense line are among the options offered to patients. The more that physicians and payers recognize the cost effectiveness of preventing complications through therapy, the more stable the demand base becomes for companies like ResMed.
In respiratory care, chronic obstructive pulmonary disease and other conditions requiring ventilatory support create additional demand for devices and software platforms. ResMed provides equipment and tools to manage these conditions, especially in home and long term care settings. Global demographic trends, including aging populations and rising rates of metabolic disease, are likely to sustain demand for such solutions in the coming years, giving ResMed a relatively predictable backdrop in its core segments.
Regulatory and reimbursement landscape
As with most medical technology companies, ResMed operates under a regulatory and reimbursement framework that can influence its financial results. Regulatory bodies in major markets, including the United States, Europe, and Asia Pacific, oversee the approval and ongoing monitoring of medical devices. Changes in regulatory expectations around safety, data security, and clinical evidence can require manufacturers to adjust their product development and documentation practices.
On the reimbursement side, public and private payers determine how therapies like sleep apnea treatment are covered and under what conditions. ResMed must navigate updates to reimbursement codes, coverage policies, and pricing structures, especially for durable medical equipment and related supplies. The companys focus on demonstrating clinical outcomes and patient adherence can help support favorable reimbursement decisions, though pressures to control healthcare costs remain an ongoing reality.
For investors, the regulatory and reimbursement landscape is important because it can affect both top line growth and margin sustainability. ResMed has a long history of working within these frameworks, but continued vigilance is needed as policies evolve. The companys investments in data driven evidence and collaboration with provider organizations are key elements in maintaining its position within this complex environment.
Digital health integration and data strategy
Digital health has become a central theme in ResMeds strategy, complementing the physical devices that have long been at the core of its business. By integrating sensors and wireless communication into sleep and respiratory devices, the company can collect data on usage patterns, therapy adherence, and performance. That data, in turn, feeds into portals and applications used by clinicians and care providers to monitor patients and adjust treatment plans.
ResMed leverages these capabilities through its various software solutions that manage out of hospital care. The data from devices can help identify patients who are not using their equipment as prescribed, allowing interventions that may improve outcomes and reduce healthcare costs. This integration of hardware, software, and data analytics is a distinguishing feature of ResMeds approach and helps it compete in a market where healthcare systems increasingly seek measurable value.
From a financial perspective, digital health offerings contribute recurring revenue and can improve customer retention, as providers who rely on ResMed software are likely to maintain long term relationships. This recurring base can reduce the cyclicality that sometimes characterizes capital equipment businesses and can support more stable revenue and margin profiles over time.
Global footprint and regional trends
ResMed operates in multiple regions worldwide, including North America, Europe, Asia Pacific, and emerging markets. Each region offers different growth dynamics and regulatory conditions. In North America, the company benefits from relatively high awareness of sleep apnea and established reimbursement systems, although competitive pressures and cost control efforts still require careful management. In Europe, variations between national health systems mean that market strategies must be tailored country by country.
Asia Pacific represents a longer term growth opportunity, as economic development and expanding healthcare infrastructure can lead to increased diagnosis and treatment of sleep disorders and respiratory conditions. ResMed has invested in developing its presence in these markets, both through direct operations and partnerships with local distributors and healthcare providers. The companys ability to adapt its offerings to different regulatory and clinical environments is important in this context.
The global nature of ResMeds business provides diversification benefits but also exposes the company to currency fluctuations and varying regulatory requirements. From an investor perspective, this diversification can help mitigate region specific risks but may also add complexity to financial analysis, as revenue and margins can shift due to macroeconomic factors beyond the companys direct control.
Competition and innovation
ResMed operates in a competitive landscape that includes other major medical device companies and specialized firms focused on sleep and respiratory care. Competitors offer alternative devices, masks, and monitoring tools, and some are also investing in digital health capabilities. To maintain and grow its market share, ResMed must continue innovating in both hardware and software.
Innovation efforts include enhancing device comfort and usability, improving mask designs to reduce leaks and increase patient satisfaction, and refining algorithms that adjust therapy parameters automatically. In software, ResMed works on improving user interfaces, analytics capabilities, and integration with electronic medical records and other data sources. These developments aim to make its products more attractive to both patients and providers.
The pace of innovation in medical technology is high, and companies that fail to keep up risk losing relevance. ResMed has historically shown a strong commitment to research and development, allocating a portion of its revenue each year to new product development and clinical studies. Maintaining this commitment will be important to sustaining the growth trajectory reflected in recent financial results.
ResMed stock and investor considerations
For investors evaluating ResMed stock, the key metrics from fiscal Q3 2024 provide a snapshot of the companys current performance. Revenue of around $1.2 billion, net income near $250 million, and diluted EPS of approximately $1.70 per share demonstrate a business that is both growing and profitable. The year over year comparison, with revenue up about 12% and earnings increasing in the low double digits, adds context to the valuation implied by a share price near $260.
ResMed stock offers exposure to structural trends in sleep and respiratory care, underpinned by aging populations and growing awareness of the importance of sleep health. At the same time, the premium valuation and proximity to record share price levels require investors to consider potential risks, including regulatory changes, competitive pressures, and macroeconomic developments. The companys emphasis on digital health and recurring revenue provides some mitigation against these risks, but does not eliminate them.
Overall, the recent financial data and market behavior suggest that ResMed remains well positioned within its sector. Investors who follow health care and medical technology will likely continue to monitor its quarterly results, product developments, and strategic initiatives to assess how the companys trajectory evolves relative to expectations.
ResMed stock price and current trading
ResMed stock, trading on Nasdaq under ticker RMD, has shown a progression from roughly $230 per share in mid 2023 to about $260 per share by mid 2024, illustrating a gain of around 13% over that period. This movement aligns with the companys underlying earnings growth and the broader market recognition of its role in sleep and respiratory care. As of that mid 2024 date, the shares were changing hands at levels close to their 52 week highs, emphasizing the markets positive view.
Going forward, the stocks performance will likely remain sensitive to new information on quarterly earnings, guidance, and sector developments. Investors typically examine how ResMed balances growth investments with profitability, how its digital health initiatives scale, and how demand patterns evolve in its core markets. The quantified metrics from recent reporting periods provide a foundation for such analysis, while the share price offers a real time reflection of sentiment.
ResMed Inc. key facts
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: NASDAQ: RMD
- Trading venue: Nasdaq
- Price (as of 15 June 2024, 16:00 ET): 260 USD
- Market capitalization: 39,000,000,000 USD (as of 15 June 2024)
- Sector / Industry: Health Care / Medical Technology
- Index membership: S&P 500
- Next earnings date: 8 August 2024
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
